Overview

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Status:
Completed

Trial end date:
2005-04-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Sirolimus, tacrolimus, and methotrexate may be effective in preventing acute graft-versus-host disease in patients who are undergoing donor stem cell transplantation. PURPOSE: This phase I/II trial is studying the side effects of sirolimus when given together with tacrolimus and methotrexate and to see how well they work in preventing acute graft-versus-host disease in patients who are undergoing donor stem cell transplantation for hematologic cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Everolimus
Methotrexate
Sirolimus
Tacrolimus